StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
DGXBullishIndustry Newsnews
High materiality7/10

Quest Diagnostics and Waters Expand At-Home HPV Testing Network Starting 2027

Oct 20, 2026, 8:17 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Higher disease-screening volumes typically drive lab utilization and revenue for large reference labs like DGX; multi-year ramp begins 2027 with Waters/BD+Quest backbone; incremental volume and payer coverage could lift margins over time.

AI summary

What happened, with direct paths to the underlying reporting

Quest Diagnostics and Waters announce a collaboration to broaden access to the FDA-cleared Onclarity Self-Collection HPV kit, expanding into clinical, health-plan, and consumer channels by 2027. The kit offers extended genotyping and supports ASCCP Enduring Risk-Based Guidelines, potentially boosting Quest's lab volumes as at-home screening reduces barriers and grows the screening population.

  • Quest Diagnostics and Waters expand at-home HPV testing nationwide from 2027. Across clinician, health plan, and consumer channels.
  • First FDA-approved HPV test with extended genotyping; supports all ASCCP guidelines. Enhances risk-based management.
  • Quest reaches one in three American adults. Footprint spans roughly half of U.S. hospitals.
  • Approximately 24 million under-screened individuals; 14,000 new cervical cancer cases annually.
  • Beginning in 2027, Quest expands access via clinician, plan, and consumer channels.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event